# **Probiotics May Prevent Antibiotic-Related Diarrhea**

## BY JEFF EVANS Senior Writer

ORLANDO, FLA. — Daily intake of a lactobacilli-fermented milk may help prevent antibiotic-associated diarrhea in hospitalized patients, Natalie A. Fortier reported at the annual meeting of the American College of Gastroenterology.

Few of the published studies on the use of probiotics to prevent antibiotic-associated diarrhea have had a strong randomized, placebo-controlled design, said Ms. Fortier of the University of Montreal.

The daily drink, which contained 50 billion colony-forming units of live Lactobacillus acidophilus and L. casei, was associated with significantly fewer cases of antibiotic-associated diarrhea (7 of 41 patients) than was a placebo drink composed of lactoserum devoid of any microorganisms (16 of 43 patients).

Ms. Fortier and her colleagues at the university defined antibiotic-associated diarrhea as three or more liquid stools in a 24-hour period in the randomized, doubleblind trial.

The researchers provided the active treatment or placebo daily to adult patients with an average age of 70 years on the 7-10 days that they were taking antibiotics and obtained follow-up from the

# Early Colorectal Ca Screening in **Minorities**

ORLANDO, FLA. — Colorectal cancer occurs at a high enough rate in African Americans and Hispanics under 50 years of age to warrant screening starting at age 40, according to Jaydutt Vadgama, Ph.D., of the Charles R. Drew University of Medicine and Science, Los Angeles.

In a retrospective study, Dr. Vadgama found that of 148 patients who had been diagnosed with colorectal cancer at the Martin Luther King/Drew Medical Center during 1996-2004, 38 (26%) were younger than 50 years of age. At diagnosis, the 38 patients had a median age of 42 years. Half of the patients under age 50 had a family history of colorectal cancer.

During 1993-1997, 46% of the 11,615 cases of colorectal cancer in African Americans and Hispanics in California occurred in patients younger than 50 years.

"Colorectal cancer screening should be considered in African Americans and Hispanics beginning at age 40 regardless of family history," the researchers suggested in a poster presentation at the annual meeting of the American College of Gastroenterology.

The college's guidelines on colorectal cancer screening, published in 2000, recommend that patients at higher than average risk for colorectal cancer should be screened by colonoscopy at an age of 40 years or 10 years younger than the age of the youngest affected relative at diagnosis, whichever is earlier.

patients for 21 days after they stopped taking antibiotics.

The patients began prophylactic treatment in the first 48 hours after starting antibiotics, which were primarily for upper respiratory tract infections.

Those with active diarrhea, GI bleeding, inflammatory bowel disease, Clostridium difficile infection in the last 3 months, a high risk of an immunocompromised state, lactose intolerance, or a regular intake of probiotics were excluded from the trial.

Diarrhea associated with C. difficile occurred less often in patients who received the active treatment (1 of 41) than in placebo patients (7 of 43), although the difference did not reach statistical significance.

Actively treated patients had a significantly shorter median length of stay in the hospital, compared with patients who received placebo (8 days vs. 10 days).

Ms. Fortier and her associates obtained their results from a multivariate analysis after controlling for risk factors for antibiotic-associated diarrhea and C. difficile-associated diarrhea as well for the fact that significantly more placebo patients received β-lactam antibiotics (67%) than did actively treated patients (41%).

Side effects-mostly of a GI nature-occurred in nearly half of patients in each group, she said.

The active and placebo preparations were provided by Bio-K+ International Inc., Laval, Que., which manufactures and markets the active treatment.

#### ZOMIG® (zolmitriptan) Tablets ZOMIG-ZMT® (zolmitriptan) Orally Disintegrating Tablets

BRIEF SUMMARY of PRESCRIBING INFORMATION

INDICATIONS AND USAGE: ZOMIG is indicated for the acute treat for the prophylactic therapy of migraine or for use in the manageme and effectiveness of ZOMIG have not been established for cl

ZOMIG should not be administered to patients with hemiplegic or basilar migraine. use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is or Drug Interactions and PRECAUTIONS: Drug Interactions). ZOMIG is contraindicated as or any of the inactive incredients

IGS: ZOMIG should only be used where a clear diagnosis of migraine has been est

Patients winn symptomate veel -avances-invente syndrome of armymmic associate with order cance accessory concurson pair to the Studied for Careb 20Ms. Convincients: A mong the new text and 2 500 patients with impaires who participated in premedual to the Careb 20Ms. The syndrome is a syndrome is a syndrome in the syndrome is a syndrome in the syndrome is a patient syndrome is a syndrome in the syndrome is a syndrome in the syndrome is a syndrome is a control distribution of the syndrome is a control syndrome is a control syndrome is a control syndrome is a syndro

nal pain. In ei Bood Pressure: As with other 5+HT, aponists, significant elevations in systemic blood pressure have be the ZMMIS ablet use, in patients with and without a history or bypertension; very really these increases in the XMMIS and the XMMIS

NMS with ther 5-HT (g-r) apporters, sensations of tightness, pain, pressure, and h tests in the precordum, threat, neek and jaw. Because animitytan may cause con-tropic suggested to a diracial following door is plotted be evaluated for the presen-tions of the sense rest or the sense of the sense of

the naise the possibility that committigan could cause toxicity in filese tassues after extended use. However, no effects on the retine relation of the toxicity the section is and in the toxicity the section is an effect of the section of the sec

The properties of the proof of

uning Menters: It is not homen whether minimized is constell in human mit. Because many drugs are excreted in human mik, cou-or in build the emerican divergent and emericant of a summary mean. La Señar a summary drugs are excreted in human mik, cou-ent to material plasma levels at 1 hours and 4 times higher than plasma levels at 4 hours. Señart levels state of effectiveness of 20 million (in padietra plasma levels at 4 hours. Señart levels state) and effectiveness of 20 million (in padietra plasma here) as the established therefore. 2004 is not recommended russ in plasma levels at 1 hours and 4 times higher than plasma levels as the señart berefore. Señart is not recommended russ in plasma levels at 1 hours and 4 times higher than plasma levels at the señart berefore. Señart is not recommende relint levels. Altono and the science of a señart berefore and the señart berefore and the señart berefore. Señart entit levels. Altono and the science of a señart berefore and the señart berefore and the señart berefore and the señart levels. Construction and the science of a señart berefore and the señart berefore and the señart berefore. Señart levels and the science of a señart berefore and a señart berefore and the señart berefore. Señart levels and the science of a señart berefore and the señart berefore and

ZOMIG® (zolmitriptan) Tablets

 $\mathbf{ZOMIG}\text{-}\mathbf{ZMT}^{\scriptscriptstyle (\!\!\!\!)}$  (zolmitriptan) Orally Disintegrating Tablets

counse contract strates, (see LL.RIFLAR, PHARMACOLLOGY: Special Populations) ADVERSE REACTIONS: Serious cardiac events, including myocardial interction, have occurred following the use of ZDMG Tables: These events are attentively are and marks these here reported in plantlers with risk factors predictive of 2D. Events reported, in these events are attentively are and marks these here reported in plantlers with risk factors predictive of 2D. Events reported, in ventiroular tactopearties, and ventificatel thrillation (see CONTRAMIDICATIONS, WARNINGS, and PRECAUTIONS). Incidence in Controlled Clinical Trials: Arroy 2.533 planters traded with ZDMG Tables in the active and plance controlled trials, on populations window (or clinical trials). Arroy 2.633 planters traded with ZDMG Tables in the active and plance controlled trials, on populations window (or clinical trials). Arroy 2.633 planters traded with ZDMG Tables in the active and plance controlled trials, on planters window (or clinical trials). Arroy 2.633 planters traded with ZDMG Tables with early backbo controlled trials, on planters window (or clinical trials). Arroy 2.633 planters traded with ZDMG Tables, and PRECAUTIONS, Weith and the trade of the total trade to the policy of the active and a substrate trade of the total trade of the policy of the set (167 or of 2.058) withdraw from the trad because of adverse operione. The most common events were parstensia, astheria, nau-sed, (clinics, pair, of the of mick to the clinicate of backboses convolution and your events. The table in the operation of the tables the operation of the tables the obvious of the operation of the tables the operation of t (167 out of 2.055) withdrew from the triab because of adverse symmetrix treated a single-market and placeho controlled triab; a single-market and placeho control treat multiple migraine attacks for up to 1 yes see, distances, pain, chest or next trightness or treatwest as adverse to treat multiple migraine attacks for up to 1 yes, see, distances, pain, chest or next trightness or treatwests control and a single-market migraine attacks for up to 1 yes and the control of the triab because of adverse experimence. Them cost common events were parsites, asshma, and yes 2.4 with EV2/R triabels in any control the ZMB in this gradition. Table 1 lists the adverse events that cocurre in the cost or in other clinical, these therearements related in a highly soleted platent to polation. In actual clinical para treat of any direct sole and the next of platent to experime plane under closely monitored conflicts of an intelled to the clinical para treat deverse overtis tappear does related, notaby paresthesia, sensation of heavines or tightness in clears.

Table 1: Adverse Experience Incidence in Five Placebo-Controlled Migraine Clinical Trials: Events Reported By ≥ 2% Patients Treated With ZOMIG Tab

Adverse Event Type	Placebo (n=401)	ZOMIG 1 mg (n=163)	ZOMIG 2.5 mg (n=498)	ZOMIG 5 mg (n=1012)
ATYPICAL SENSATIONS	6%	12%	12%	18%
Hypesthesia	1%	1%	1%	2%
Paresthesia (all types)	2%	5%	7%	9%
Sensation warm/cold	4%	6%	5%	7%
PAIN AND PRESSURE SENSATIONS	7%	13%	14%	22%
Chest-pain/tightness/pressure and/or heaviness	1%	2%	3%	4%
Neck/throat/jaw-pain/tightness/pressure	3%	4%	7%	10%
Heaviness other than chest or neck	1%	1%	2%	5%
Pain-location specified	1%	2%	2%	3%
Other-pressure/tightness/heaviness	0%	2%	2%	2%
DIGESTIVE	8%	11%	16%	14%
Dry mouth	2%	5%	3%	3%
Dyspepsia	1%	3%	2%	1%
Dysphagia	0%	0%	0%	2%
Nausea	4%	4%	9%	6%
NEUROLOGICAL	10%	11%	17%	21%
Dizziness	4%	6%	8%	10%
Somnolence	3%	5%	6%	8%
Vertigo	0%	0%	0%	2%
OTHER				
Asthenia	3%	5%	3%	9%
Palpitations	1%	0%	<1%	2%
Mvalgia	<1%	1%	1%	2%
Myasthenia	<1%	0%	1%	2%
Sweating	1%	0%	2%	3%

penerally well tolerated. Across all doses, most adverse reactions were mild and transient not of adverse events in controlled clinical traits was not affeted by gender, weight, or a nos of presence of any There were insufficient data to assess the impact of near on the **nts**. In the paragraphs that follow, the frequencies of liss commonly reported adverse clini-clude events disserved in open and uncontrolled studies. There has the temporation of 20MG in their can re, variability associated with adverse event reporting, the terminology used to describe table integency estimates provided. Event Integencies are classical as the number adv listed in the previous table, these to general to be informatine, and these not reasoure adv listed in the previous table, there be to general to be informatine, and these not reasoure adv listed in the previous table, these to general to be informatine, and these not negocide the previous table. These to general to be informatine, and these not negocide the previous table. These to general to be informatine, and these not negocide tables to the previous table. These to general to be informatine, and these not negocide tables to the previous table. These to general to be informatine, and these not the student tables to the student table.

Interpret vas doma, Balancen verser verser ganose, inter vers ganose, motomostopenia, esoinophila and in program vas doma, Balancen verser verser ganose, motomostopenia, esoinophila and in the production in the second second second second second second second second programs in the production in the second second second second second second second programs in the production in the second second second second second second second second production in the second s

Coronary artery vasospasm: transient myocardial ischemia, angina pectoris, and myoc

Careforessolar: coronay artery vasopasm; transent impocana scorena, argina pettors, are myoaraia intercion. Digetter: very respectivisetima informa events notuding spine interfactori, scherm e colls, and gestrinistenia intercion is sis have been reported; these may present as bloody durinks or abdominar pain (see WARNINSS). **Neurological:** As with other scale impainer intermations including other 5-first galons; there have been rare reports of headach **General:** As with other 5-first galons; there have been very rare reports of anaphysics or anaphysicabi reactions in patient ing 20MG. There have been rare reports of hypersanshifty reactions, including arginologia.

DRUG ABUSE AND DEPENDENCE: The abuse potential of ZOMIG has not been assessed in clinical trials OVERDOSAGE: There is no experience with clinical overdoes. Volunteers neceving single 50 mg and does of n introde statutor. The return that the de 20ME loss is to so see clinical. ModMACQDOF1, and clinical statutor is a set of the source of the antimitation is a set of severe introduction. Interestive are proceeding including statutors are introduction and control and control and monitoring and separat the cardiovascular syster hemodalysis or printeral dialysis has on the plasma contentions of administrations of administration.

ZOMIG and ZOMIG-ZMT are trademarks of the AstraZeneca group of companies. © AstraZeneca 2003

ZOMIG<sup>®</sup> (zolmitriptan) Tablets lanufactured for: ed for: a Pharmaceuticals LP I, DE 19850 Iarmaceuticals, Inc.

64209-00 Rev 10/03

7MG5027

By: IPR Pharmaceuti Carolina, PR 00984 ZOMIG-ZMT<sup>®</sup> (zolmitriptan) Orally Disintegrating Tablets Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, DE 15000 By: CIMA Labs, Inc. Frien Prairie, MN 55344

## medPointe

te Health Somerset, New Jersev 08873